-
Mashup Score: 16Facts and hopes for PET imaging-derived immunotherapy biomarkers - 6 month(s) ago
Abstract. Current immunotherapies have brought major progress in cancer treatments, but not all patients benefit. Therefore, insight into reasons for treatment failure and optimal biomarkers for patient selection are warranted. Current approved biomarkers for cancer immunotherapy do not provide insight into characteristics across tumor lesions in a patient or their heterogeneity. Here, whole-body positron emission tomography (PET) imaging with specific tracers may provide support. Moreover, the biodistribution of cell therapies and complex molecules, such as bispecific antibodies, can be visualized by PET imaging, and repeat PET imaging allows to study the whole-body kinetics of the immune response. In this review, we present the status of using PET imaging-derived biomarkers for patients with cancer receiving immunotherapy. Next, the hopes and scientific challenges ahead to optimize current PET imaging biomarker development and to discover novel PET-derived baseline and dynamic biomar
Source: aacrjournals.orgCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 19Plasma ctDNA as a treatment response biomarker in metastatic cancers: evaluation by the RECIST working group - 6 month(s) ago
Abstract. Early indicators of metastatic cancer response to therapy are important for evaluating new drugs and stopping ineffective treatment. The Response Evaluation Criteria in Solid Tumors (RECIST) based on repeat cancer imaging are widely adopted in clinical trials, are used to identify active regimens that may change practice, and contribute to regulatory approvals. However, these criteria do not provide insight before 6 – 12 weeks of treatment and typically require that patients have measurable disease. Recent data suggests that measuring on-treatment changes in the amount or proportion of circulating tumor DNA (ctDNA) in peripheral blood plasma may accurately identify responding and non-responding cancers at earlier time points. Over the past year, the RECIST working group has evaluated current evidence for plasma ctDNA kinetics as a treatment response biomarker in metastatic cancers and early endpoint in clinical trials, to identify areas of focus for future research and valida
Source: aacrjournals.orgCategories: General Medicine News, Oncologists1Tweet-
The paper "Plasma ctDNA as a treatment response biomarker in metastatic cancers: evaluation by the RECIST working group" is out https://t.co/LBLKHkLW99
-
-
Mashup Score: 19Plasma ctDNA as a treatment response biomarker in metastatic cancers: evaluation by the RECIST working group - 6 month(s) ago
Abstract. Early indicators of metastatic cancer response to therapy are important for evaluating new drugs and stopping ineffective treatment. The Response Evaluation Criteria in Solid Tumors (RECIST) based on repeat cancer imaging are widely adopted in clinical trials, are used to identify active regimens that may change practice, and contribute to regulatory approvals. However, these criteria do not provide insight before 6 – 12 weeks of treatment and typically require that patients have measurable disease. Recent data suggests that measuring on-treatment changes in the amount or proportion of circulating tumor DNA (ctDNA) in peripheral blood plasma may accurately identify responding and non-responding cancers at earlier time points. Over the past year, the RECIST working group has evaluated current evidence for plasma ctDNA kinetics as a treatment response biomarker in metastatic cancers and early endpoint in clinical trials, to identify areas of focus for future research and valida
Source: aacrjournals.orgCategories: General Medicine News, Oncologists1Tweet-
The paper "Plasma ctDNA as a treatment response biomarker in metastatic cancers: evaluation by the RECIST working group" is out https://t.co/LBLKHkLW99
-
-
Mashup Score: 114Whole-Body HER2 Heterogeneity Identified on HER2 PET in HER2-Negative, -Low, and -Positive Metastatic Breast Cancer - 6 month(s) ago
Understanding which patients with human epidermal growth factor receptor 2 (HER2)–negative or –low metastatic breast cancer (MBC) benefit from HER2-targeted strategies is urgently needed. We assessed the whole-body heterogeneity of HER2 expression on 89Zr-trastuzumab PET (HER2 PET) and the diagnostic performance of HER2 PET in a large series of patients, including HER2-negative and -low MBC. Methods: In the IMPACT-MBC study, patients with newly diagnosed and nonrapidly progressive MBC of all subtypes were included. Metastasis HER2 status was determined by immunohistochemistry and in situ hybridization.89Zr-trastuzumab uptake was quantified as SUVmax and SUVmean. HER2 immunohistochemistry was related to the quantitative 89Zr-trastuzumab uptake of all metastases and corresponding biopsied metastasis, uptake heterogeneity, and qualitative scan evaluation. A prediction algorithm for HER2 immunohistochemistry positivity based on uptake was developed. Results: In 200 patients, 89Zr-trastuzum
Source: jnm.snmjournals.orgCategories: General Medicine News, Oncologists1Tweet-
Our paper: "Whole-Body HER2 Heterogeneity Identified on HER2 PET in HER2-Negative, -Low, and -Positive Metastatic Breast Cancer" is out https://t.co/cHh4qKAsMe https://t.co/9K5BeF59eC
-
-
Mashup Score: 1Cardiotoxicity of Immune Checkpoint Inhibitors - 7 month(s) ago
This systematic review and meta-analysis updates data on the incidence of cardiovascular adverse events in clinical trials of immune checkpoint inhibitors alone and in combination therapies and provides recommendations for management among patients treated for cancer.
Source: jamanetwork.comCategories: General Medicine News, Oncologists1Tweet-
Cardiotoxicity of Immune Checkpoint Inhibitors https://t.co/7E8UpD35zb
-
-
Mashup Score: 1Promovendus computer science/kunstmatige intelligentie/… - 8 month(s) ago
Ben jij een ambitieuze onderzoeker met een passie voor computer science, kunstmatige intelligentie of technische…
Source: werkenbijumcg.nlCategories: General Medicine News, Oncologists1Tweet-
RT @rsnfehrmann: Interesting PhD-position! https://t.co/CgJnrp1onx
-
-
Mashup Score: 12Blocking the GLP-1 receptor may help fight colorectal cancer - 9 month(s) ago
A new study in mice suggests that blocking the GLP-1 receptor may help defend against colorectal cancer, begging the question: Do drugs like Wegovy and Zepbound have ill effects in cancer?
Source: www.medicalnewstoday.comCategories: General Medicine News, Oncologists2Tweet-
RT @DanielJDrucker: Should you block or activate the GLP-1 receptor to combat cancer? https://t.co/eZ3PJdBdiL
-
-
Mashup Score: 12Blocking the GLP-1 receptor may help fight colorectal cancer - 9 month(s) ago
A new study in mice suggests that blocking the GLP-1 receptor may help defend against colorectal cancer, begging the question: Do drugs like Wegovy and Zepbound have ill effects in cancer?
Source: www.medicalnewstoday.comCategories: General Medicine News, Oncologists2Tweet-
RT @DanielJDrucker: Should you block or activate the GLP-1 receptor to combat cancer? https://t.co/eZ3PJdBdiL
-
-
Mashup Score: 11Offline: It is time to take cancer more seriously - 11 month(s) ago
The Lancet has published two Commissions in 2024 addressing the commonest cancers among men and women: prostate cancer (led by Nicholas James) and breast cancer (led by Charlotte Coles). As we were preparing these Commissions for publication, we considered writing an editorial linking the two cancers. But we hesitated. Surely these conditions are distinguished by their differences, not their similarities. Breast cancer is preventable. No such possibilities exist for prostate cancer. As our Commission on Prostate Cancer concluded: “The projected rise in prostate cancer cases cannot be prevented by lifestyle changes or public health interventions.” Yet, observing their launches and listening to the debates they provoked suggests that these cancers have more in common than might be appreciated—synergies that have important implications for accelerating cancer prevention and control.
Source: www.thelancet.comCategories: General Medicine News, Oncologists2Tweet-
Offline: It is time to take cancer more seriously - The Lancet https://t.co/LMYAlesbsW
-
-
Mashup Score: 11Offline: It is time to take cancer more seriously - 11 month(s) ago
The Lancet has published two Commissions in 2024 addressing the commonest cancers among men and women: prostate cancer (led by Nicholas James) and breast cancer (led by Charlotte Coles). As we were preparing these Commissions for publication, we considered writing an editorial linking the two cancers. But we hesitated. Surely these conditions are distinguished by their differences, not their similarities. Breast cancer is preventable. No such possibilities exist for prostate cancer. As our Commission on Prostate Cancer concluded: “The projected rise in prostate cancer cases cannot be prevented by lifestyle changes or public health interventions.” Yet, observing their launches and listening to the debates they provoked suggests that these cancers have more in common than might be appreciated—synergies that have important implications for accelerating cancer prevention and control.
Source: www.thelancet.comCategories: General Medicine News, Oncologists2Tweet-
Offline: It is time to take cancer more seriously - The Lancet https://t.co/LMYAlesbsW
-
Our paper "Facts and hopes for PET imaging-derived immunotherapy biomarkers" is out @DerkGroot https://t.co/iEGrCOeBb2